- Previous Close
0.9400 - Open
0.9393 - Bid 0.8435 x 100
- Ask 0.9168 x 100
- Day's Range
0.8400 - 0.9400 - 52 Week Range
0.2070 - 13.5580 - Volume
868,244 - Avg. Volume
4,808,740 - Market Cap (intraday)
1.507M - Beta (5Y Monthly) -0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-12.3800 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
silexion.com--
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: SLXN
View More
Performance Overview: SLXN
Trailing total returns as of 2025-01-17, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLXN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLXN
View MoreValuation Measures
Market Cap
1.63M
Enterprise Value
3.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.13%
Return on Equity (ttm)
-116.66%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.35M
Diluted EPS (ttm)
-12.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.78M
Total Debt/Equity (mrq)
8.94%
Levered Free Cash Flow (ttm)
-305.62k
Research Analysis: SLXN
View MoreCompany Insights: SLXN
SLXN does not have Company Insights